Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2004-2-23
pubmed:abstractText
Oct-2, a transcription factor expressed in the B lymphocyte lineage and in the developing CNS, functions through of a number of discrete protein domains. These include a DNA-binding POU homeodomain flanked by two transcriptional activation domains. In vitro studies have shown that the C-terminal activation domain, a serine-, threonine- and proline-rich sequence, possesses unique qualities, including the ability to activate transcription from a distance in a B cell-specific manner. In this study, we describe mice in which the endogenous oct-2 gene has been modified through gene targeting to create a mutated allele, oct-2DeltaC, which encodes Oct-2 protein isoforms that lack all sequence C-terminal to the DNA-binding domain. Surprisingly, despite the retention of the DNA-binding domain and the glutamine-rich N-terminal activation domain, the truncated protein(s) encoded by the oct-2DeltaC allele are unable to rescue any of the previously described defects exhibited by oct-2 null mice. Homozygous oct-2DeltaC/DeltaC mice die shortly after birth, and B cell maturation, B-1 cell self renewal, serum Ig levels, and B lymphocyte responses to in vitro stimulation are all reduced or absent, to a degree equivalent to that seen in oct-2 null mice. We conclude that the C-terminal activation domain of Oct-2 is required to mediate the unique and indispensable functions of the Oct-2 transcription factor in vivo.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
172
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2962-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:14978099-Amino Acid Sequence, pubmed-meshheading:14978099-Animals, pubmed-meshheading:14978099-Animals, Newborn, pubmed-meshheading:14978099-Antigens, CD36, pubmed-meshheading:14978099-B-Lymphocyte Subsets, pubmed-meshheading:14978099-Cell Differentiation, pubmed-meshheading:14978099-Cell Line, pubmed-meshheading:14978099-Cells, Cultured, pubmed-meshheading:14978099-DNA-Binding Proteins, pubmed-meshheading:14978099-Gene Targeting, pubmed-meshheading:14978099-Immunoglobulins, pubmed-meshheading:14978099-Mice, pubmed-meshheading:14978099-Mice, Inbred C57BL, pubmed-meshheading:14978099-Mice, Knockout, pubmed-meshheading:14978099-Mitogens, pubmed-meshheading:14978099-Molecular Sequence Data, pubmed-meshheading:14978099-Mutagenesis, Insertional, pubmed-meshheading:14978099-Octamer Transcription Factor-2, pubmed-meshheading:14978099-Peptide Fragments, pubmed-meshheading:14978099-Protein Structure, Tertiary, pubmed-meshheading:14978099-Survival Analysis, pubmed-meshheading:14978099-Trans-Activators, pubmed-meshheading:14978099-Transcription Factors
pubmed:year
2004
pubmed:articleTitle
All known in vivo functions of the Oct-2 transcription factor require the C-terminal protein domain.
pubmed:affiliation
The Walter and Eliza Hall Institute, Parkville, Victoria, Australia. corcoran@wehi.edu.au
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't